LENZ THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
LENZ THERAPEUTICS, INC. (LENZ) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$225.00K, a 803.13% decline year-over-year.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $171.00K.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $32.00K.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $203.00K.
- LENZ THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$225.00K derived: sum of 2 quarters · filed 2026-03-24 | $0.00 10-K · filed 2026-03-24 | |
| 2025-09-30 | -$225.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $225.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $203.00K derived: sum of 2 quarters · filed 2026-03-24 | $203.00K 10-K · filed 2026-03-24 | |
| 2024-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $32.00K 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 10-K · filed 2025-03-19 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |